402 results on '"Pérol, M."'
Search Results
2. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
3. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
4. Prise en charge des CBNPC oligométastatiques synchrones: Management of synchronous non-small oligometastatic lung cancer: update 2023
5. Algorithme thérapeutique des CBNPC sans mutation addictive: Algorithm of NSCLC management outside oncogenic addiction
6. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
7. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
8. Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne: Advanced stage NSCLC excluding oncogenic addiction: second-line systemic treatments
9. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
10. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
11. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
12. Les CBNPC de stades avancés hors addiction oncogénique: les traitements systémiques de deuxième ligne
13. Traitements de première ligne dans les CBNPC avancés, en l’absence d’addiction oncogénique (incluant le traitement de maintenance et les anti-angiogéniques)
14. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
15. Algorithme thérapeutique des CBNPC sans mutation addictive
16. Stratégies et modalités des immunothérapies : espacement des doses, durée
17. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
18. Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en l’absence d’addiction oncogénique
19. Les essais cliniques princeps en immuno-oncologie dans les cancers broncho-pulmonaires
20. Traitement de 1re ligne des CBNPC métastatiques sans addiction oncogénique: First-line treatment of metastatic NSCLC without oncogenic addiction
21. Traitement de première ligne et de maintenance dans les CBNPC avancés en l’absence d’addiction oncogénique
22. Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable: Therapeutic algorithm for NSCLC without actionable molecular abnormalities
23. 78P Final analysis of the French real-world study EVIDENS: Effectiveness, safety & quality of life at 36 months of nivolumab in advanced non-small cell lung cancer (NSCLC)
24. 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis
25. Traitement de seconde ligne et au-delà des cancers bronchopulmonaires non à petites cellules de stade IV en l’absence d’addiction oncogénique
26. Première ligne des CBNPC avancés sans addiction oncogénique : quel traitement pour quel patient ?: Frontline treatment of advanced NSCLC without oncogenic addiction: which treatment for which patient?
27. Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne: Advanced stage NSCLC excluding oncogenic addiction: Second-line systemic treatments
28. Traitements systémiques de première ligne dans les CBNPC avancés en l’absence d’addiction oncogénique: Frontline systemic treatment of advanced NSCLC without oncogenic addiction
29. Traitement de 1re ligne des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique
30. Stratégie de maintenance dans les carcinomes bronchiques non à petites cellules de stade IV
31. 202P The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti-PD-1 treatment in patients with non-small cell lung cancer
32. Traitement des CBNPC au stade métastatique. Acquis et bonnes pratiques
33. Choix d'un traitement de maintenance dans les cancers bronchiques non à petites cellules avancés
34. Quelle organisation pour la prise en charge des cancers thoraciques en 2008 ? Résultats d’une enquête sur les pratiques en oncologie thoracique en région Rhône-Alpes
35. Prise en charge des carcinomes muco-épidermoïdes bronchiques de l’adulte
36. Traitement d’induction et de maintenance des CBNPC au stade métastatique
37. Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]
38. La stratégie de maintenance en première ligne de traitement dans les cancers bronchiques non à petites cellules avancés
39. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
40. LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
41. 147P Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies
42. 1455P Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
43. 1401P Impact of KRAS mutation on non-small cell lung cancer survival outcomes
44. 1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
45. 1407P Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
46. 1402P Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
47. 1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
48. 1369P BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
49. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
50. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.